Market Overview

UPDATE: Merck Posts Upbeat Q3 Profit

Related MRK
Agilent Company Dako, Announces FDA Approval of New Companion Diagnostic for Lung Cancer
Roth Capital Upgrades ANI Pharmaceuticals To Buy On Valuation
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status (Zacks)

Merck & Co (NYSE: MRK) reported a drop in its third-quarter profit.

Merck's quarterly profit declined to $1.12 billion, or $0.38 per share, down from $1.73 billion, or $0.56 per share, in the year-earlier quarter. Its adjusted earnings fell to $0.92 per share from $0.95 per share.

Its sales dropped to $11.03 billion from $11.49 billion. However, analysts were estimating earnings of $0.87 per share on revenue of $11.1 billion.

Merck now expects 2013 adjusted earnings of $3.48 to $3.52 per share, versus its earlier forecast of $3.45 to $3.55 per share.

Merck shares gained 1.53% to $47.25 in pre-market trading.

Posted-In: profitEarnings News Guidance


Related Articles (MRK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters